CSF3 and Thrombocytopenia: When comparing the rates of hematologic and non-hematologic adverse events between the etoposide and the G-CSF alone groups, the rates of grade II–IV thrombocytopenia (63.0% vs. 31.0%; p = 0.031) and grade I–IV nausea (14.8% vs. 0%; p = 0.048) were significantly higher in the etoposide group.